Report Highlights

U.S. Primary Cells: Market Overview

The U.S. primary cells market is structured around three major demand channels: academic and government research institutions, biopharmaceutical drug discovery operations, and cell therapy contract development and manufacturing organizations (CDMOs). Federal research funding through the National Institutes of Health, which distributed USD 35.3 billion in grants in FY2024, is the single largest demand driver. Unlike most life sciences markets, the government acts as both a direct procurer — through intramural NIH programs — and an indirect demand engine through extramural grant awards that fund primary cell purchases at recipient institutions. The private sector leads in product standardization and supply chain innovation, with Lonza, Thermo Fisher Scientific, and STEMCELL Technologies collectively accounting for the majority of commercial catalog supply.

Market structure is moderately consolidated at the supplier level but highly fragmented at the end-user level, with over 4,000 academic research institutions, 1,500 biotechnology companies, and numerous hospital-based translational research centers each procuring primary cells independently. Pricing is not subject to federal price controls, but NIH grant budget guidelines indirectly cap what institutions will pay per lot. The market has been reshaped fundamentally by two forces: the FDA Modernization Act 2.0 of 2022, which removed mandatory animal testing for IND and NDA submissions, and the 21st Century Cures Act of 2016, which accelerated FDA review timelines and increased demand for physiologically predictive human cell models. Both statutes have elevated primary human cells from research reagents to critical regulatory-grade testing materials.

Policy-Driven Growth in Primary Cells in the U.S.

The FDA Modernization Act 2.0 (H.R. 2565, enacted December 29, 2022) is the most consequential policy mechanism for this market. By removing the statutory animal testing requirement from the Federal Food, Drug, and Cosmetic Act's IND application pathway, the legislation formally permits — and increasingly expects — sponsors to substitute human primary cell-based in vitro assays and organ-on-chip platforms. FDA's Center for Drug Evaluation and Research (CDER) issued draft guidance in 2023 on New Alternative Methods (NAMs), directing sponsors on how primary cell assay data can satisfy safety and pharmacology endpoints. Each new drug program that pivots to NAMs requires validated primary cell lots, translating directly into recurring commercial procurement contracts worth USD 50,000 to USD 500,000 per program per year depending on therapeutic area.

The National Institutes of Health Common Fund's Somatic Cell Genome Editing (SCGE) program, which allocated USD 190 million over six years beginning in 2018, has sustained a dedicated pipeline of primary cell demand for gene editing feasibility studies, with continuation funding expected through FY2026. Additionally, the Advanced Research Projects Agency for Health (ARPA-H), established by Congress in 2022 with an initial USD 1 billion appropriation, explicitly funds programs requiring human tissue-derived primary cell models for disease mechanism research. ARPA-H's Biomedical Data Fabric and Resilient Bioeconomy programs both mandate use of human primary cells over immortalized lines in awarded contracts, institutionalizing demand at the federal procurement level and creating recurring purchase obligations for ARPA-H grantees.

Regulatory Barriers and Compliance Costs

The primary regulatory barrier for commercial primary cell suppliers is compliance with the FDA's Current Good Manufacturing Practice (cGMP) requirements under 21 CFR Parts 1271 and 820, which govern human cells, tissues, and cellular and tissue-based products (HCT/Ps). The FDA's Center for Biologics Evaluation and Research (CBER) administers HCT/P registration and inspection. Suppliers seeking to provide primary cells for therapeutic or regulatory-grade applications must register with CBER, maintain donor eligibility records, implement infectious disease testing per 21 CFR 1271.85, and pass biennial facility inspections. The cost of achieving and maintaining cGMP HCT/P compliance is estimated at USD 2 million to USD 5 million annually for a mid-sized supplier, representing a prohibitive barrier for smaller entrants and limiting competitive supply expansion at the premium tier.

Importation of primary cells from non-U.S. sources faces additional compliance friction under CBER import requirements, FDA Establishment Registration, and in certain cases, the Convention on International Trade in Endangered Species (CITES) when non-human primate-derived cells are involved — administered jointly by the U.S. Fish and Wildlife Service and the CDC. For suppliers of primary cells intended for use in FDA submissions, the agency's 2024 draft guidance on Organotypic Models for Regulatory Use introduced a new layer of documentation requirements: cell characterization data, donor demographic traceability, and passage-number certification must accompany each lot. Meeting these requirements adds an estimated 15 to 25 additional working days to lot release timelines, creating supply delays that cascade through client research schedules and increasing per-lot administrative costs by 20 to 30 percent.

Policy-Created Opportunities in U.S. Primary Cells

The Biden-era Executive Order on Advancing Biotechnology and Biomanufacturing Innovation (EO 14081, September 2022) directed federal agencies to prioritize domestic biomanufacturing capacity, including human cell and tissue supply chains. In response, the Department of Health and Human Services released a National Bioeconomy Blueprint in 2023 that identified primary human cell supply as a critical input for domestic cell therapy manufacturing. This creates a procurement preference for U.S.-sourced primary cells in federally funded programs and positions domestic suppliers to benefit from HHS and DOD procurement programs. The Department of Defense's Defense Health Agency has specifically funded primary cell procurement for traumatic injury and burn research through its Congressionally Directed Medical Research Programs (CDMRP), with USD 85 million in annual allocations relevant to tissue-based research.

The Centers for Medicare and Medicaid Services (CMS) coverage expansion for CAR-T and other cell therapies — with coverage determinations issued under National Coverage Analysis 310.1 — has accelerated commercialization of cell therapy products, indirectly driving demand for the primary T-cells and stem cells used in manufacturing process development. Suppliers that can provide cGMP-compliant leukapheresis-derived primary T-cells with standardized donor profiles are positioned to capture long-term supply agreements from cell therapy CDMOs. Furthermore, the NIH's National Center for Advancing Translational Sciences (NCATS) Tissue Chip for Drug Screening program, funded at USD 30 million annually, mandates primary human cell use in all platform development contracts, creating a stable, recurring federal demand segment entirely insulated from commercial market fluctuations.

Market at a Glance

Leading Market Participants

• Lonza Group
• Thermo Fisher Scientific
• STEMCELL Technologies
• PromoCell GmbH
• Zen-Bio
• Cell Biologics
• Axol Bioscience
• iXCells Biotechnologies
• Asterand Bioscience (part of BioIVT)
• Corning Life Sciences

Regulatory and Policy Environment

The foundational legislation governing the U.S. primary cells market is the Public Health Service Act Section 361 (42 U.S.C. 264), implemented through 21 CFR Part 1271 — Human Cells, Tissues, and Cellular and Tissue-Based Products. CBER within FDA is the administering agency, responsible for HCT/P establishment registration, donor eligibility determination, and current good tissue practice (CGTP) enforcement. All commercial suppliers of human-derived primary cells must register with CBER's HCT/P Registry and submit to inspection. As of 2024, CBER has intensified inspection frequency following a backlog created during the COVID-19 moratorium period, with warning letters issued to three commercial primary cell suppliers between 2022 and 2024 for donor eligibility record deficiencies. Compared to the European Union, where the EU Tissues and Cells Directive (2004/23/EC) and its implementing directives create a harmonized but more permissive national competent authority framework, the U.S. CBER pathway is more centralized and prescriptive, increasing compliance costs but also providing clearer regulatory certainty for sponsors using primary cells in submissions.

Upcoming regulatory changes with direct market impact include FDA's anticipated finalization of the Draft Guidance for Industry on New Alternative Methodologies for Safety Testing, expected in late 2025 or early 2026, which will formally specify how primary cell assay data must be formatted, validated, and submitted in IND and NDA packages. This guidance will establish primary cells as a defined regulatory input — not merely a research tool — triggering a wave of supplier qualification audits by pharmaceutical sponsors. Additionally, CBER is expected to issue updated CGTP inspection criteria by Q2 2026 that impose stricter environmental monitoring and cell characterization documentation requirements. These changes will raise the compliance floor across the industry, consolidating market share among well-capitalized suppliers and forcing smaller operators to either invest significantly in quality systems or exit the regulatory-grade segment entirely.

Long-Term Policy Outlook for U.S. Primary Cells

By 2030, the regulatory trajectory strongly favors institutionalization of primary human cells as the default safety testing substrate for drug development under FDA oversight. The ICCVAM Authorization Act, administered through the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, is expected to drive coordinated federal agency adoption of primary cell-based testing protocols across EPA, FDA, and NIH programs by 2027. This interagency alignment will eliminate the fragmented agency-by-agency acceptance of NAMs that currently creates uncertainty for sponsors and will establish consistent primary cell specification standards across federal procurement. Suppliers that achieve multi-agency recognized qualification status will gain durable competitive advantages that cannot be rapidly replicated.

The anticipated reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) by 2026 is expected to include provisions for domestic primary cell and human tissue stockpiling as part of national biodefense preparedness, following lessons from COVID-19 vaccine and therapeutic development timelines. BARDA's existing Broad Agency Announcements for medical countermeasure development already reference primary cell-based assay platforms as preferred methodologies, and a PAHPA reauthorization with explicit bioeconomy provisions will formalize federal spending on primary cell infrastructure through at least 2032. This policy direction effectively guarantees a stable federal demand floor that insulates the U.S. primary cells market from the cyclical private-sector R&D spending fluctuations that affect other life sciences reagent categories.